Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.

The role of miR-26a in carcinogenesis appears to be a complicated one, in the sense that both oncogenic and tumor suppressive effects were reported in cancers such as glioblastoma and hepatocellular carcinoma, respectively. Here, we report for the first time that miR-26a is downregulated in breast cancer specimens and cell lines and its transient transfection initiates apoptosis of breast cancer cell line MCF7 cells. Furthermore, retrovirus-delivered miR-26a impairs the in vitro colony forming and in vivo tumor-loading ability of MCF7 cells. Subsequently, MTDH and EZH2 are identified as two direct targets of miR-26a and they are significantly upregulated in breast cancer. MCF7 xenografts with exogenous miR-26a show that a decrease in expression of both MTDH and EZH2 is accompanied by an increase in apoptosis. Moreover, knockdown of MTDH causes apoptosis while reexpression of MTDH partially reverses the proapoptotic effect of miR-26a in MCF7 cells. Our findings suggest that miR-26a functionally antagonizes human breast carcinogenesis by targeting MTDH and EZH2.

[1]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[2]  B. Ljung,et al.  Deletion of two separate regions on chromosome 3p in breast cancers. , 1994, Cancer research.

[3]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[4]  Daniel Chourrout,et al.  Genome Regulation by Polycomb and Trithorax Proteins , 2007, Cell.

[5]  A. Donfrancesco,et al.  Deregulated expression of miR-26a and Ezh2 in Rhabdomyosarcoma , 2009, Cell cycle.

[6]  M. Brandi,et al.  Osteogenic Differentiation of Human Adipose Tissue‐Derived Stem Cells Is Modulated by the miR‐26a Targeting of the SMAD1 Transcription Factor , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[8]  Jinu Kim,et al.  MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer , 2010 .

[9]  Wei Huang,et al.  Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship , 2010, Proceedings of the National Academy of Sciences.

[10]  Xianrang Song,et al.  Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells , 2009, Journal of experimental & clinical cancer research : CR.

[11]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[12]  Libing Song,et al.  Astrocyte Elevated Gene-1 is a Novel Prognostic Marker for Breast Cancer Progression and Overall Patient Survival , 2008, Clinical Cancer Research.

[13]  P. Fisher,et al.  Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis , 2009, Proceedings of the National Academy of Sciences.

[14]  T. Mustelin,et al.  A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells , 2007, Cell Death and Differentiation.

[15]  Eva E. Rufino-Palomares,et al.  MicroRNAs as Oncogenes and Tumor Suppressors , 2013 .

[16]  J. Lieberman,et al.  let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.

[17]  N. Voirin,et al.  Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype , 2009, British Journal of Cancer.

[18]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Neilson,et al.  Zcchc11-dependent uridylation of microRNA directs cytokine expression , 2009, Nature Cell Biology.

[20]  H. Zentgraf,et al.  The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells , 2008, International journal of cancer.

[21]  R. Dahiya,et al.  Chromosome 3p24‐26 and 3p22‐12 loss in human prostatic adenocarcinoma , 1997, International journal of cancer.

[22]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[23]  Jing Liang,et al.  Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[24]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[25]  P. Fisher,et al.  Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc , 2006, Proceedings of the National Academy of Sciences.

[26]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[27]  Tara L. Naylor,et al.  microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Place,et al.  Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity , 2007, Oncogene.

[29]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[30]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[31]  Kristian Helin,et al.  The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. , 2007, Genes & development.

[32]  M. Reiss,et al.  MTDH Activation by 8 q 22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer , 2008 .

[33]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Theillet,et al.  p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.

[35]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[36]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[37]  V. Beneš,et al.  Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. , 2009, Cancer research.

[38]  Reuven Agami,et al.  The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. , 2009, Genes & development.